Jump Financial LLC Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Jump Financial LLC purchased a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 24,946 shares of the company’s stock, valued at approximately $371,000.

A number of other large investors have also recently made changes to their positions in the stock. abrdn plc purchased a new stake in ALX Oncology in the fourth quarter worth approximately $986,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ALX Oncology by 445.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after buying an additional 4,706 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology in the fourth quarter worth $28,000. Hsbc Holdings PLC purchased a new stake in ALX Oncology during the third quarter valued at $168,000. Finally, SG Americas Securities LLC lifted its holdings in ALX Oncology by 201.4% in the fourth quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock valued at $452,000 after acquiring an additional 20,279 shares during the period. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $13.17 on Friday. The firm’s 50 day simple moving average is $13.99 and its two-hundred day simple moving average is $13.33. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21. The company has a market capitalization of $686.16 million, a P/E ratio of -3.54 and a beta of 1.30. ALX Oncology Holdings Inc. has a 1-year low of $3.94 and a 1-year high of $17.83.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Research analysts expect that ALX Oncology Holdings Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ALXO has been the subject of a number of recent research reports. Stifel Nicolaus restated a “hold” rating and set a $14.00 price target (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.83.

Insider Transactions at ALX Oncology

In related news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now directly owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the sale, the insider now directly owns 330,349 shares in the company, valued at $5,265,763.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Insiders sold a total of 102,000 shares of company stock valued at $1,442,680 over the last 90 days. Company insiders own 33.40% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.